ODN/Pam2 - PulmotectAlternative Names: ODN-M362/Pam2CSK4; Pam2/ODN; Pam2CSK4/ODN-M362; PUL-042
Latest Information Update: 13 Oct 2016
At a glance
- Originator Pulmotect
- Class Antisense oligonucleotides; Lipopeptides
- Mechanism of Action Immunostimulants; Toll-like receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Pneumocystis pneumonia
Most Recent Events
- 28 Feb 2014 Phase-I clinical trials in Pneumocystis pneumonia (prevention, in volunteers) in USA (Inhalation)